Lu-177-RM2
177Lu-RM2 (177Lu-BAY-1017858) is a molecule corresponding to a different [...]
Lu-177-PNT2002
177Lu-PNT2002 (formerly 177Lu-PSMA-I&T is a peptide developed by the [...]
Lu-177-DTPA-Omburtamab
177Lu-DTPA-Omburtamab (177Lu-Burtomab) is a monoclonal murine antibody, targeted against [...]
Y-90-Besilesomab
90Y-Besilesomab is the therapeutic analogue of the 99mTc-labeled murine [...]
I-131-Weimeisheng
131I-Weimeisheng (131I-Tumor Necrosis Therapy mAb injection) is a radiolabeled [...]
I-131-Metuximab
131I-Metuximab (brand name Licartin) is a radiolabeled murine antibody [...]
Patient Management with Lu-177–PSMA-617 in the Clinic
Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate [...]
Health Policy Partnership Framework
The Oncidium foundation is endorsing the Health Policy Partnership Framework, [...]
PSMA Theranostics: Current Landscape and Future Outlook
Cancers 2021, 13(16), 4023; https://doi.org/10.3390/cancers13164023, August 10, 2021, by Hanbo [...]
Lu-177-PSMA-617A Added to Standard Therapy
VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard [...]